To investigate the effect of bound thrombin, a complex of α-thrombin with fibrin fragments derived from clots, on proliferation and migration of cultured rabbit vascular smooth muscle cells, cell proliferation was measured by WST-1 reagent and migration was evaluated by counting migrated cells through pores of cell culture insert (8 μm size) after 48-hour treatment with bound thrombin (10 U/ml). To examine the role of an embryonic myosin heavy chain isoform (SMemb) in these effects by bound thrombin, the cells were subsequently treated for 48 h with an siRNA expression vector (ORF-2/pSilencer) directed against the open reading frame of SMemb mRNA. SMemb and plasminogen activator inhibitor-1 mRNA expressions were measured by Northern blot analysis. Bound thrombin significantly increased SMemb mRNA expression by 1.4 ± 0.01-fold and significantly increased plasminogen activator inhibitor-1 mRNA expression by 2.65 ± 0.69-fold (p < 0.01 vs. PBS treatment for each), which were abolished by treatment with ORF-2/pSilencer. Although bound thrombin had no effect on cell proliferation, bound thrombin significantly increased migration by 1.93 ± 0.20-fold (p < 0.05). ORF-2/pSilencer treatment significantly reduced the bound thrombin-stimulated migration activity by 1.28 ± 0.15-fold (p < 0.05). Thus, SMemb plays an important role in bound thrombin-induced cell migration activity of cultured vascular smooth muscle cells.

Keywords:
Bound thrombin, SMemb gene, siRNA, Cultured vascular smooth muscle cells, Migration
1.
Kastrati A, Schomig A, Elezi S, Dirschinger J, Mehilli J, Schuhlen H, Blasini R, Neumann FJ: Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999;100:1285–1290.
2.
Radke PW, Klues HG, Haager PK, Hoffmann R, Kastrau F, Reffelmann T, Janssens U, vom Dahl J, Hanrath P: Mechanisms of acute lumen gain and recurrent restenosis after rotational atherectomy of diffuse in-stent restenosis: a quantitative angiographic and intravascular ultrasound study. J Am Coll Cardiol 1999;34:33–39.
3.
Schofer J, Rau T, Schluter M, Mathey DG: Short-term results and intermediate-term follow-up of laser wire recanalization of chronic coronary artery occlusions: a single-center experience. J Am Coll Cardiol 1997;30:1722–1728.
4.
Kuro-o M, Nagai R, Nakahara K, Katoh H, Tsai RC, Tsuchimochi H, Yazaki Y, Ohkubo A, Takaku F: cDNA cloning of a myosin heavy chain isoform in embryonic smooth muscle and its expression during vascular development and in arteriosclerosis. J Biol Chem 1991;266:3768–3773.
5.
Francis CW, Markham RE Jr, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ: Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983;102:220–230.
6.
Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ: Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064–2071.
7.
Reganon E, Ferrando F, Vila V, Villa P, Martinez-Sales V, Fayos L, Ruano M, Aznar J: Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone. Haemostasis 1998;28:99–105.
8.
Becker DL, Fredenburgh JC, Stafford AR, Weitz JI: Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. Adv Exp Med Biol 1997;425:55–66.
9.
Weitz JI, Leslie B, Hudoba M: Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97:544–552.
10.
Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP: Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993;91:1877–1883.
11.
Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385–391.
12.
Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH: The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 1991;17:77B–88B.
13.
Moons AH, Levi M, Peters RJ: Tissue factor and coronary artery disease. Cardiovasc Res 2002;53:313–325.
14.
Kinjoh K, Nakamura M, Sunagawa M, Kosugi T: Isolation of bound thrombin consisting of thrombin and fibrin N-terminal fragments from clot lysate. Haematologia (Budap) 2002;32:457–465.
15.
Kinjoh K, Nakamura M, Zeng G, Sunagawa M, Eguchi Y, Kosugi T: Bound thrombin from crushed clots was composed of a-thrombin and N-terminal regions of a and g chains of fibrinogen. Pathophysiol Haemost Thromb 2002;32:165–173.
16.
Zeng G, Kinjoh K, Nakamura M, Kosugi T: The activity of postclotting thrombins on platelet activation was identical to that of native thrombin. J Jap Coll Angiol 2002;42:25–31.
17.
Shimada S, Sunagawa M, Nakamura M, Kosugi T: Bound thrombin-induced upregulation of myosin heavy chain isoform, SMemb messenger RNA expression in cultured rabbit vascular smooth muscle cells. Int J Tissue React 2003;25:137–148.
18.
Shimada S, Sunagawa M, Hanashiro K, Nakamura M, Kosugi T: RNA interference targeting embryonic myosin heavy chain isoform inhibited mRNA expressions of phenotype markers in rabbit cultured vascular smooth muscle cells. Heart Vessels 2007;22:41–47.
19.
Yoshinaga M, Sunagawa M, Shimada S, Nakamura M, Murayama S, Kosugi T: Argatroban, specific thrombin inhibitor, induced phenotype change of cultured rabbit vascular smooth muscle cells. Eur J Pharmacol 2003;461:9–17.
20.
Nakamura M, Kinjoh K, Hanashiro K, Tokeshi Y, Sunagawa M, Kosugi T: The bound-thrombin was uncompetitivey inhibited by argatroban. Br J Haematol 1998;102:138–139.
21.
Nakamura M, Sunagawa M, Kosugi T, Sperelakis N: Actin filament disruption inhibits L-type Ca2+ channel current in cultured vascular smooth muscle cells. Am J Physiol Cell Physiol 2000;279:C480–C487.
22.
Rovner AS, Thompson MM, Murphy RA: Two different heavy chains are found in smooth muscle myosin. Am J Physiol 1986;250:C861–C870.
23.
Al-Fakhri N, Chavakis T, Schmidt-Woll T, Huang B, Cherian SM, Bobryshev YV, Lord RS, Katz N, Preissner KT: Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol Chem 2003;384:423–435.
24.
Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R: Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994;93:1266–1274.
25.
Pauly RR, Bilato C, Sollott SJ, Monticone R, Kelly PT, Lakatta EG, Crow MT: Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation 1995;91:1107–1115.
26.
Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11–25.
27.
Katsuda S, Okada Y: Vascular smooth muscle cell migration and extracellular matrix. J Atheroscler Thromb 1994;1(suppl 1):S34–S38.
28.
Stefansson S, McMahon GA, Petitclerc E, Lawrence DA: Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003;9:1545–1564.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.